Methisazone in Progressive Vaccinia
| Autor: | Henry Brainerd, Ernest Jawetz, Lavelle Hanna |
|---|---|
| Rok vydání: | 1967 |
| Předmět: |
Thiosemicarbazones
Drug media_common.quotation_subject Vaccinia virus Antiviral Agents Virus chemistry.chemical_compound Immunity Progressive vaccinia Vaccinia Humans Medicine Smallpox Smallpox vaccine Methisazone media_common business.industry General Medicine Middle Aged medicine.disease Hodgkin Disease Virology chemistry Immunology Female business Smallpox Vaccine |
| Zdroj: | New England Journal of Medicine. 276:620-622 |
| ISSN: | 1533-4406 0028-4793 |
| DOI: | 10.1056/nejm196703162761106 |
| Popis: | N-METHYLISATIN-β-THIOSEMICARBAZONE (methisazone) is an antiviral chemical of unquestioned activity both in vitro and in man. In cell-culture systems its activity is manifest by the failure of vaccinia-infected cells to synthesize a "late" structural protein of the virus. Thus, the drug prevents assembly of complete infectious virus particles if it is present during a major part of the replicative cycle.1 In man methisazone is a highly effective prophylactic drug upon exposure to smallpox.2 Ample statistical proof supports the practical usefulness of the drug in preventing serious disease, provided it is administered within one to three days after exposure. The therapeutic potential . . . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|